Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: December 2008
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Eli Lilly and Company v. Sun Pharmaceutical Industries Ltd. et al.1:08-cv-01629; filed December 4, 2008 in the Southern District of Indiana Infringement…
-
December 8-9, 2008 – Pharmaceutical and Biotech Patent Opinion Writing*** (American Conference Institute) – Atlanta, GA January 3-7, 2009 – 26th Annual National CLE Conference (Law Education Institute) – Vail, CO January 12-13, 2009 – Pharmaceutical and Biotech Patent Opinion Writing*** (American Conference Institute) – San Diego, CA January 20-21, 2009 – Bio/Pharmaceutical Summit on…
-
Law Seminars International (LSI) will be holding its Fourth Annual Conference on Best Practices in Patent Monetization conference on January 29-30, 2009 in San Francisco, CA. During the conference, LSI's faculty will offer presentations on the following topics: • How do you get useful patents?• Creating and implementing decision rules for patent portfolio mining and…
-
C5 (UK) will be holding its Pharma/Biotech Patent Litigation conference on February 17-18, 2009 in Amsterdam, Netherlands. At this conference, C5 faculty will offer presentations on the following topics: • Review of 2008 European case law developments;• Assessing the likely ramifications of the German olanzapine decision;• Inventive step post Angiotech: Has UK patent law returned…
-
By Donald Zuhn — On Wednesday, the biotechnology, chemical, and pharmaceuticals (BCP) technology groups at the U.S. Patent and Trademark Office held their most recent quarterly customer partnership meeting. During the last of six presentations, Associate Solicitor Janet Gongola outlined a new training module that the Office has begun using to instruct examining corps…
-
By Mark Chael — On December 2nd, Mylan, Inc. and Mylan Pharmaceuticals, Inc. announced that they had settled their dispute with Novartis Pharmaceuticals Corp., Novartis Corp., and Novartis International AG over a generic version of Novartis' Femara® tablets. According to the press release, Femara® tablets, which are used in the treatment of breast cancer,…
-
By Donald Zuhn — As we reported yesterday, Director Jon Dudas of the U.S. Patent and Trademark Office filed a Notice of Appeal in the District Court for the District of Columbia on November 28th, appealing the Court's decision in Wyeth v. Dudas to the United States Court of Appeals for the District of Columbia Circuit…
-
By Sherri Oslick — Earlier this week, Impax Laboratories, Inc. and Medicis Pharmaceutical Corp. announced that they have entered a Joint Development Agreement and a Settlement and License Agreement that brings to an end their pending lawsuit over Impax's plans to manufacture a generic version of Medics' Solodyn® (minocycline hydrochloride extended release tablets, used…
-
By Donald Zuhn — Last Friday, U.S. Patent and Trademark Office Director Jon Dudas filed a Notice of Appeal in the District Court for the District of Columbia appealing the Court's September 30th decision in Wyeth v. Dudas to the United States Court of Appeals for the District of Columbia Circuit. Director Dudas challenges District Judge…
-
Medegen MMS, Inc. v. ICU Medical, Inc. (Fed. Cir. 2008) By Kevin E. Noonan — The Federal Circuit recently had the opportunity to appreciate firsthand the frustrations of district court judges with its review of claim construction under Markman v. Westview Instruments, Inc. This teaching came in a dissenting opinion from the Honorable Vaughn…
Patent Docs 